Oncoinvent ASA BRRGF Stock
Oncoinvent ASA Price Chart
Oncoinvent ASA BRRGF Financial and Trading Overview
| Oncoinvent ASA stock price | 2.5 USD |
| Previous Close | 1.77 USD |
| Open | 1.77 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.77 - 1.77 USD |
| 52 Week Range | 1.77 - 1.77 USD |
| Volume | 100 USD |
| Avg. Volume | 0 USD |
| Market Cap | 207.74M USD |
| Beta (5Y Monthly) | 1.884291 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.26 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BRRGF Valuation Measures
| Enterprise Value | 6.4M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 534.0349 |
| Price/Book (mrq) | 1.773547 |
| Enterprise Value/Revenue | 16.455 |
| Enterprise Value/EBITDA | -0.021 |
Trading Information
Oncoinvent ASA Stock Price History
| Beta (5Y Monthly) | 1.884291 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.77 USD |
| 52 Week Low | 1.77 USD |
| 50-Day Moving Average | 1.77 USD |
| 200-Day Moving Average | 1.77 USD |
BRRGF Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 102.69M |
| Float | 51.88M |
| Short Ratio | N/A |
| % Held by Insiders | 34.58% |
| % Held by Institutions | 18.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -78569.14% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.92% |
| Return on Equity (ttm) | -127.76% |
Income Statement
| Revenue (ttm) | 389K USD |
| Revenue Per Share (ttm) | 0.004 USD |
| Quarterly Revenue Growth (yoy) | -49.70% |
| Gross Profit (ttm) | 389K USD |
| EBITDA | -305553984 USD |
| Net Income Avi to Common (ttm) | -302121984 USD |
| Diluted EPS (ttm) | -0.37 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 150.8M USD |
| Total Cash Per Share (mrq) | 1.7 USD |
| Total Debt (mrq) | 275K USD |
| Total Debt/Equity (mrq) | 0.31 USD |
| Current Ratio (mrq) | 2.139 |
| Book Value Per Share (mrq) | 0.998 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -288231008 USD |
| Levered Free Cash Flow (ttm) | -176587872 USD |
Profile of Oncoinvent ASA
| Country | United States |
| State | N/A |
| City | Bergen |
| Address | Møllendalsbakken 9 |
| ZIP | 5009 |
| Phone | 47 55 96 11 59 |
| Website | https://www.bergenbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29 |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Q&A For Oncoinvent ASA Stock
What is a current BRRGF stock price?
Oncoinvent ASA BRRGF stock price today per share is 2.5 USD.
How to purchase Oncoinvent ASA stock?
You can buy BRRGF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oncoinvent ASA?
The stock symbol or ticker of Oncoinvent ASA is BRRGF.
Which industry does the Oncoinvent ASA company belong to?
The Oncoinvent ASA industry is Biotechnology.
How many shares does Oncoinvent ASA have in circulation?
The max supply of Oncoinvent ASA shares is 156.64M.
What is Oncoinvent ASA Price to Earnings Ratio (PE Ratio)?
Oncoinvent ASA PE Ratio is now.
What was Oncoinvent ASA earnings per share over the trailing 12 months (TTM)?
Oncoinvent ASA EPS is -5.26 USD over the trailing 12 months.
Which sector does the Oncoinvent ASA company belong to?
The Oncoinvent ASA sector is Healthcare.